SCHEMBL849666

SCHEMBL849666

CCCc1cccc(-c2cccc(C(=O)O)c2)c1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BCL2 P10415 1/20 0.59
KMO O15229 2/20 0.58
NR4A2 P43354 1/20 0.52
RXRA P19793 2/20 0.51
RXRB P28702 2/20 0.51
LTB4R2 Q9NPC1 1/20 0.51
PPARG P37231 1/20 0.50
FOLH1 Q04609 1/20 0.50
PTPN11 Q06124 1/20 0.50
DHFR P00374 1/20 0.50
FNTA P49354 2/20 0.49
FNTB P49356 2/20 0.49
PGGT1B P53609 1/20 0.49
MRGPRX4 Q96LA9 1/20 0.49
LMNA P02545 1/20 0.49
GAA P10253 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28369070 0.90 BCL2 (0.56) BCL2KMONR4A2LTB4R2PTPN11
SCHEMBL991080 0.90 FOLH1 (0.61) FOLH1MRGPRX4
SCHEMBL30354557 0.90 FOLH1 (0.61) FOLH1MRGPRX4
SCHEMBL850998 0.89 KMO (0.61) BCL2KMOLTB4R2PPARGPTPN11
SCHEMBL12894987 0.86 BCL2 (0.78) BCL2KMONR4A2RXRARXRB
SCHEMBL13554034 0.83 CYP4F2 (0.63) BCL2DHFRFNTAFNTBPGGT1B
SCHEMBL30777855 0.82 CTSS (0.51) BCL2
SCHEMBL196298 0.82 CTSS (0.51) BCL2
SCHEMBL5519447 0.81 KMO (0.63) BCL2KMONR4A2RXRARXRB
SCHEMBL4533749 0.80 AGXT (0.52) BCL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487517-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-08 US disclosed
US-9487517-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-08 US disclosed
US-9487517-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-08 US disclosed
US-20160016956-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-01-21 US disclosed
EP-2433940-B9 SPIROIMIDAZOLONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2015-10-28 EP disclosed
US-9169254-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-10-27 US disclosed
US-9169254-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-10-27 US disclosed
US-9169254-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-10-27 US disclosed
EP-2433940-B1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2014-09-24 EP disclosed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 US disclosed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 US disclosed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 US disclosed
EP-2433940-A1 SPIROIMIDAZOLONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2012-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE WNK3, REN, SGK3 BCL2 3498/4885KMO 4049/4885NR4A2 1252/4885
US-20160016956-A1 SPIROIMIDAZOLONE DERIVATIVE WNK3, REN, SGK3 BCL2 3498/4885KMO 4049/4885NR4A2 1252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.